Mary Rusckowski to Antibodies, Neoplasm
This is a "connection" page, showing publications Mary Rusckowski has written about Antibodies, Neoplasm.
Connection Strength
0.587
-
Liu G, Dou S, Chen X, Chen L, Liu X, Rusckowski M, Hnatowich DJ. Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted. Cancer Biother Radiopharm. 2010 Dec; 25(6):757-62.
Score: 0.091
-
Liu G, Dou S, Pretorius PH, Liu X, Chen L, Rusckowski M, Hnatowich DJ. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector. Q J Nucl Med Mol Imaging. 2010 Jun; 54(3):333-40.
Score: 0.085
-
Liu G, Dou S, Liang M, Chen X, Rusckowski M, Hnatowich DJ. The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size. Eur J Cancer. 2009 Nov; 45(17):3098-103.
Score: 0.084
-
He J, Liu G, Dou S, Gupta S, Rusckowski M, Hnatowich D. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies. Bioconjug Chem. 2007 May-Jun; 18(3):983-8.
Score: 0.071
-
Rusckowski M, Doherty PW, Virzi F, Hnatowich DJ. A simple in vitro method of screening panels of monoclonal antibodies for tumor binding. J Immunol Methods. 1985 Feb 11; 76(2):375-82.
Score: 0.061
-
Rusckowski M, Fogarasi M, Fritz B, Hnatowich DJ. Effect of endogenous biotin on the applications of streptavidin and biotin in mice. Nucl Med Biol. 1997 Apr; 24(3):263-8.
Score: 0.035
-
Hnatowich DJ, Fritz B, Virzi F, Mardirossian G, Rusckowski M. Improved tumor localization with (strept)avidin and labeled biotin as a substitute for antibody. Nucl Med Biol. 1993 Feb; 20(2):189-95.
Score: 0.026
-
Hnatowich DJ, Mardirossian G, Rusckowski M, Fogarasi M, Virzi F, Winnard P. Directly and indirectly technetium-99m-labeled antibodies--a comparison of in vitro and animal in vivo properties. J Nucl Med. 1993 Jan; 34(1):109-19.
Score: 0.026
-
Griffin TW, Brill AB, Stevens S, Collins JA, Bokhari F, Bushe H, Stochl MC, Gionet M, Rusckowski M, Stroupe SD, et al. Initial clinical study of indium-111-labeled clone 110 anticarcinoembryonic antigen antibody in patients with colorectal cancer. J Clin Oncol. 1991 Apr; 9(4):631-40.
Score: 0.023
-
Hnatowich DJ, Rusckowski M, Brill AB, Siebecker DA, Misra H, Mardirossian G, Bushe H, Rescigno A, Stevens S, Johnson DK, et al. Pharmacokinetics in patients of an anti-carcinoembryonic antigen antibody radiolabeled with indium-111 using a novel diethylenetriamine pentaacetic acid chelator. Cancer Res. 1990 Nov 15; 50(22):7272-8.
Score: 0.023
-
Liu G, Dou S, Baker S, Akalin A, Cheng D, Chen L, Rusckowski M, Hnatowich DJ. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49. Cancer Biol Ther. 2010 Oct 15; 10(8):767-74.
Score: 0.023
-
Chen X, Dou S, Liu G, Liu X, Wang Y, Chen L, Rusckowski M, Hnatowich DJ. Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting. Bioconjug Chem. 2008 Aug; 19(8):1518-25.
Score: 0.019
-
Liu G, Dou S, Rusckowski M, Hnatowich DJ. An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector. Mol Cancer Ther. 2008 May; 7(5):1025-32.
Score: 0.019